Vidofludimus is a selective inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH), which plays a key role in pyrimidine biosynthesis in proliferating immune cells. This mechanism reduces the proliferation of activated lymphocytes, thereby exerting immunomodulatory effects. It is primarily used in the treatment of autoimmune diseases, including multiple sclerosis (MS), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriasis, and systemic lupus erythematosus (SLE). By inhibiting inflammatory processes, Vidofludimus helps reduce inflammation, modulate the immune response, provide symptom relief, and slow disease progression. Its good oral bioavailability supports convenient long-term therapy, enhancing patient compliance and quality of life.